Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2017 · 10-Q
Revenue$102.01K$102.01K−1.9% vs Q2 2016 Net Income-$8.05M-$8.05MN/M vs Q2 2016 EPS Diluted-$3.12-$3.12N/M vs Q2 2016 Operating Income-$5,888,253N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,606,412N/M Margins · derivedOperating margin-5772.2%+3824.2 pt vs Q2 2016
Net margin-7887.2%+1922.7 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end